Show Menu

A fully integrated developer and manufacturer of polyclonal therapeutics, targeting infectious disease and acute toxic events

News: Archive for May 2024

Wellcome Grant for MicroPharm’s International Phase II Clinical Trial of C. diff. Infection treatment, OraCAb

Wales-based MicroPharm Limited (‘MicroPharm’) has been awarded funding of up to £2.8m from Wellcome to undertake a Phase II clinical trial of oral therapeutic drug, OraCAb®, for the treatment of non-life-threatening C. difficile infection (‘C. diff.’ or ‘CDI’).

Read the full story

Posted on: Wednesday, 8th May 2024